Are P2Y12 inhibitors superior to aspirin for long-term secondary prevention of cardiovascular disease?

Stephanie Carlina Thrombosis Service, Hamilton General Hospital, Hamilton, Canada;b Department of Medicine, McMaster University, Hamilton, CanadaCorrespondence[email protected]

https://orcid.org/0000-0003-1111-919X View further author information

John Eikelbooma Thrombosis Service, Hamilton General Hospital, Hamilton, Canada;b Department of Medicine, McMaster University, Hamilton, Canada;c Population Health Research Institute, Hamilton, Canada

https://orcid.org/0000-0003-4126-1285 View further author information

Click to increase image sizeClick to decrease image size

Declaration of interest

S. Carlin has received honoraria from BMS/Pfizer, and advisory board fees from AZ and Servier. J. Eikelboom has received honoraria and/or research support from Anthos, AZ, Bayer, BI, BMS, DSI, Ionis, Janssen, Pfizer, Servier, and USV. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.

Additional information

Funding

This paper was not funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Are P2Y12 inhibitors superior to aspirin for long-term secondary prevention of cardiovascular disease?

Information for

Open access

Opportunities

Help and information

Are P2Y12 inhibitors superior to aspirin for long-term secondary prevention of cardiovascular disease?

Declaration of interest

Reviewer disclosures

Correction Statement

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature